相关实验视频

Updated: Jul 15, 2025

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Published on: June 18, 2020

用于甲状腺癌治疗的回氧/pH反应性空心二氧化纳米颗粒

Jinren Liu¹, Changzhi Guo¹, Chunxiang Li²

¹Department of Molecular Imaging, School of Medical Technology, Qiqihar Medical University, Qiqihar, China.

Frontiers in chemistry

|October 2, 2023

概括

这项研究开发了一种针对甲状腺癌的新型纳米药物递送系统 (MnO2/CDDP@PDA-Cy5.5 NPs). 该系统增强了西斯普拉丁 (CDDP) 的疗效,降低了毒性,并使诊断成像成为可能.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
在瘤学瘤学.

背景情况:

甲状腺癌的治疗面临着西斯普拉丁 (CDDP) 疗效和全身毒性的挑战.
开发有针对性的药物输送系统对于改善抗癌治疗和最大限度地减少副作用至关重要.

研究的目的:

合成和描述一种新的纳米药物递送系统,MnO2/CDDP@PDA-Cy5.5NP,用于增强甲状腺癌治疗.
改善西斯普拉丁 (CDDP) 药物加载,控制药物释放,并减少目标外毒性.
在体内评估纳米系统的诊断和治疗能力.

主要方法:

空心二氧化纳米颗粒 (MnO2 NPs) 用模板方法制备.
西斯丁 (CDDP) 被加载到MnO2NP中,然后用聚多巴胺 (PDA) 和Cy5.5.5进行修改.
纳米药物输送系统 (MnO2/CDDP@PDA-Cy5.5 NPs) 的特点是它对瘤微环境 (TME) 的反应.
在体内研究中使用磁共振成像 (MRI) 来追踪瘤积累和评估治疗疗效.

主要成果:

MnO2/CDDP@PDA-Cy5.5 NP在酸性或氧化还原条件下显示CDDP的触发释放,产生Mn2+用于MRI对比.
在体内MRI证实了NP通过增强透性和保留 (EPR) 效应的显著瘤积累.
与自由CDDP相比,纳米系统显示显著提高了对甲状腺癌的治疗疗效.
该系统具有双重诊断 (MRI) 和治疗功能.

结论:

MnO2/CDDP@PDA-Cy5.5 NPs代表了一种有前途的甲状腺癌治疗纳米药物输送系统.
这种系统提供了更好的抗癌疗效和降低了全身毒性.
智能药物释放机制和MRI引导的输送突出了其在精密瘤学的潜力.

关键词:

西斯普拉丁 (cisplatin) 是一种制剂.增强的透性和保留效应.有空洞的二氧化.磁共振成像技术的使用纳米药物输送系统是纳米药物输送系统.

更多相关视频

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

Biofunctionalization of Magnetic Nanomaterials

Biofunctionalization of Magnetic Nanomaterials

Published on: July 16, 2020

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Redox Titration: Other Oxidizing and Reducing Agents

Redox Titration: Other Oxidizing and Reducing Agents

Besides iodine, other oxidizing or reducing agents can serve as titrants in redox titrations. Common oxidizing titrants include KMnO4, cerium(IV), and K2Cr2O7. The choice of oxidizing titrants depends on factors like stability, cost, analyte strength, and reaction rate between the analyte and titrant. KMnO4 is a strong oxidizing titrant that reduces from Mn(VII) to Mn(II) in a highly acidic solution, simultaneously oxidizing the analyte to a higher oxidation state. In this case, KMnO4 acts as a...

Redox Reactions

Redox Reactions

Oxidation-reduction or redox reactions involve the transfer of electrons from one molecule or atom to another. When an atom gains an electron, another atom must lose an electron, meaning oxidation and reduction must occur together. Since the redox occurs in pairs, the atom that gets oxidized is also called the reducing agent or reductant, and the atom that is reduced is also called the oxidizing agent or oxidant. A straightforward way to remember the definitions of oxidation and reduction is...